

Hep C dug-drug interaction

		Sofosbuvir	Daclatasvir	Velpatasvir
NRTIs	ABC			
	3TC/FTC			
	TDF			*
NNRTIs	EFV		**	
	ETV		**	
	NVP		**	
PIs	ATV/r		**	
	LPV/r			
INSTIs	RAL			
	DTG			

*VEL increased TDF AUC by 30-80% when co-administered. No effect on the pharmacokinetic parameters of VEL. Need to monitor for TDF-associated adverse reactions.

**DCV dose should be increased to 90mg when co-administered with EFV or NVP, reduced to 30 mg when co-administered with ATV/r

Amiodarone Warning: Co-administration of Sofosbuvir/Velpatasvir with amiodarone can cause serious symptomatic bradycardia and should be avoided.

Antacid: Use caution with antacids when taking Velpatasvir, as its solubility decreases with lower acidity.

Use drug interaction checker developed by University of Liverpool whenever co-administering a new drug with DAAs.

<https://www.hep-druginteractions.org/checker>